Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QM1114-DP in moderate to severe glabellar lines
NCT05146999Phase 3Completed
- Sponsor
- Galderma
- Start
- May 2022
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glabellar lines comparing Active arm - QM1114-DP with Inactive arm - Placebo (2 arms). Primary endpoint: Global Aesthetic Improvement Scale (GAIS) at Month 1. Started May 2022; status: completed.
02
Drugs
relabotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT05146999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05146999.